News

June, 2018

Attendance at DIT Oncology Congress China

June, 2018

Attendance at 2018 BIO International in Boston, USA.

February, 2018

Attendance at DCAT, New York

December, 2017

Attendance at Arab Health Exhibition 2018, Dubai

March, 2017

Jylamvo, Therakind’s 2 mg/ml oral solution of methotrexate, granted a Europe-wide Marketing Authorisation by the EMA

January, 2017

EMA announces positive opinion for Jylamvo, Therakind’s 2 mg/ml oral solution of methotrexate

April, 2016

Therakind is accepted onto the Mayor's International Business Programme

Therakind selected to participate in the Mayor's Export Programme

February, 2015

Therakind receives funding for simple reusable intranasal device

December, 2014

July, 2013

Therakind awarded further funding after successfully completing first phase in the development of a Hypoglycaemia treatment

May, 2013

Therakind awarded second European Union FP7 research grant for sedative medicine in paediatric intensive care

May, 2013

Therakind awarded European Union FP7 research grant for sedative medicine in noenatal intensive care

October, 2012

Therakind awarded funding to develop a simple device to enable rapid treatment of Hypoglycaemia

September, 2012

Therakind speak at the 4th conference of the EuPFi in Prague on successful PUMA application

August, 2012

Agreement with Indosys Ltd to develop a product for treating Hypoglycaemia

September, 2011

Granted European marketing authorisation for treatment of acute seizures

June, 2010

Sale of interest in product